Clinical trial · Observational
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Using Single-cell Sequencing to Explore Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are: * Provide profiles of TME between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer * Investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Immunotherapy | — | UNRESOLVED | — |
| Tumor Microenvironment | Gastric Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gastroscopic biopsy | Procedure | — | UNRESOLVED |
| SOX plus PD-1 inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Pre-treatment
- description
- Advanced gastric cancer patients prior to receiving combined immunotherapy and chemotherapy
- interventionNames
- Drug: SOX plus PD-1 inhibitor
- Procedure: Gastroscopic biopsy
- label
- Post-treatment
- description
- Advanced gastric cancer patients who have received 2 to 8 cycles of combined immunotherapy and chemotherapy
- interventionNames
- Drug: SOX plus PD-1 inhibitor
- Procedure: Gastroscopic biopsy
- label
- Response
- description
- Advanced gastric cancer patients who have achieved complete response (CR) or partial response (PR) after receiving combined immunotherapy and chemotherapy
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Non-bedridden, aged 18 to 70 years old; * Eastern Cooperative Oncology Group (ECOG) score is 0 to 1; * Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1; * Advanced gastric cancer; * Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab Exclusion Criteria: * History of other malignant diseases in the last 5 years; * Prior chemotherapy, radiotherapy or immunotherapy; * Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.
References
Publications (0)
Data not yet available